715 related articles for article (PubMed ID: 33408342)
21. Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study.
Karuna S; Li SS; Grant S; Walsh SR; Frank I; Casapia M; Trahey M; Hyrien O; Fisher L; Miner MD; Randhawa AK; Polakowski L; Kublin JG; Corey L; Montefiori D;
PLoS Med; 2021 Dec; 18(12):e1003868. PubMed ID: 34871308
[TBL] [Abstract][Full Text] [Related]
22. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.
Boonyaratanakornkit J; Morishima C; Selke S; Zamora D; McGuffin S; Shapiro AE; Campbell VL; McClurkan CL; Jing L; Gross R; Liang J; Postnikova E; Mazur S; Lukin VV; Chaudhary A; Das MK; Fink SL; Bryan A; Greninger AL; Jerome KR; Holbrook MR; Gernsheimer TB; Wener MH; Wald A; Koelle DM
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33320842
[TBL] [Abstract][Full Text] [Related]
23. Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination.
Sariol CAA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina-Rodríguez A; Cruz L; Stone ETT; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AKK; Brien JDD; Espino AMM
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696403
[TBL] [Abstract][Full Text] [Related]
24. Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India.
Shrivastava S; Palkar S; Shah J; Rane P; Lalwani S; Mishra AC; Arankalle VA
Am J Trop Med Hyg; 2021 Jun; 105(2):401-406. PubMed ID: 34138748
[TBL] [Abstract][Full Text] [Related]
25. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity.
Nielsen SS; Vibholm LK; Monrad I; Olesen R; Frattari GS; Pahus MH; Højen JF; Gunst JD; Erikstrup C; Holleufer A; Hartmann R; Østergaard L; Søgaard OS; Schleimann MH; Tolstrup M
EBioMedicine; 2021 Jun; 68():103410. PubMed ID: 34098342
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.
Seow J; Graham C; Merrick B; Acors S; Pickering S; Steel KJA; Hemmings O; O'Byrne A; Kouphou N; Galao RP; Betancor G; Wilson HD; Signell AW; Winstone H; Kerridge C; Huettner I; Jimenez-Guardeño JM; Lista MJ; Temperton N; Snell LB; Bisnauthsing K; Moore A; Green A; Martinez L; Stokes B; Honey J; Izquierdo-Barras A; Arbane G; Patel A; Tan MKI; O'Connell L; O'Hara G; MacMahon E; Douthwaite S; Nebbia G; Batra R; Martinez-Nunez R; Shankar-Hari M; Edgeworth JD; Neil SJD; Malim MH; Doores KJ
Nat Microbiol; 2020 Dec; 5(12):1598-1607. PubMed ID: 33106674
[TBL] [Abstract][Full Text] [Related]
28. The kinetics of humoral response and its relationship with the disease severity in COVID-19.
Ren L; Zhang L; Chang D; Wang J; Hu Y; Chen H; Guo L; Wu C; Wang C; Wang Y; Wang Y; Wang G; Yang S; Dela Cruz CS; Sharma L; Wang L; Zhang D; Wang J
Commun Biol; 2020 Dec; 3(1):780. PubMed ID: 33311543
[TBL] [Abstract][Full Text] [Related]
29. Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan.
Takeshita M; Nishina N; Moriyama S; Takahashi Y; Uwamino Y; Nagata M; Aoki W; Masaki K; Ishii M; Saya H; Kondo Y; Kaneko Y; Suzuki K; Fukunaga K; Takeuchi T;
Virology; 2021 Mar; 555():35-43. PubMed ID: 33450669
[TBL] [Abstract][Full Text] [Related]
30. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.
Dispinseri S; Secchi M; Pirillo MF; Tolazzi M; Borghi M; Brigatti C; De Angelis ML; Baratella M; Bazzigaluppi E; Venturi G; Sironi F; Canitano A; Marzinotto I; Tresoldi C; Ciceri F; Piemonti L; Negri D; Cara A; Lampasona V; Scarlatti G
Nat Commun; 2021 May; 12(1):2670. PubMed ID: 33976165
[TBL] [Abstract][Full Text] [Related]
31. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
[TBL] [Abstract][Full Text] [Related]
32. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome.
Röltgen K; Powell AE; Wirz OF; Stevens BA; Hogan CA; Najeeb J; Hunter M; Wang H; Sahoo MK; Huang C; Yamamoto F; Manohar M; Manalac J; Otrelo-Cardoso AR; Pham TD; Rustagi A; Rogers AJ; Shah NH; Blish CA; Cochran JR; Jardetzky TS; Zehnder JL; Wang TT; Narasimhan B; Gombar S; Tibshirani R; Nadeau KC; Kim PS; Pinsky BA; Boyd SD
Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33288645
[TBL] [Abstract][Full Text] [Related]
33. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.
Tang MS; Case JB; Franks CE; Chen RE; Anderson NW; Henderson JP; Diamond MS; Gronowski AM; Farnsworth CW
Clin Chem; 2020 Dec; 66(12):1538-1547. PubMed ID: 32894750
[TBL] [Abstract][Full Text] [Related]
34. Functional Analysis of Human and Feline Coronavirus Cross-Reactive Antibodies Directed Against the SARS-CoV-2 Fusion Peptide.
Vanderheijden N; Stevaert A; Xie J; Ren X; Barbezange C; Noppen S; Desombere I; Verhasselt B; Geldhof P; Vereecke N; Stroobants V; Oh D; Vanhee M; Naesens LMJ; Nauwynck HJ
Front Immunol; 2021; 12():790415. PubMed ID: 35069571
[TBL] [Abstract][Full Text] [Related]
35. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
Piccoli L; Park YJ; Tortorici MA; Czudnochowski N; Walls AC; Beltramello M; Silacci-Fregni C; Pinto D; Rosen LE; Bowen JE; Acton OJ; Jaconi S; Guarino B; Minola A; Zatta F; Sprugasci N; Bassi J; Peter A; De Marco A; Nix JC; Mele F; Jovic S; Rodriguez BF; Gupta SV; Jin F; Piumatti G; Lo Presti G; Pellanda AF; Biggiogero M; Tarkowski M; Pizzuto MS; Cameroni E; Havenar-Daughton C; Smithey M; Hong D; Lepori V; Albanese E; Ceschi A; Bernasconi E; Elzi L; Ferrari P; Garzoni C; Riva A; Snell G; Sallusto F; Fink K; Virgin HW; Lanzavecchia A; Corti D; Veesler D
Cell; 2020 Nov; 183(4):1024-1042.e21. PubMed ID: 32991844
[TBL] [Abstract][Full Text] [Related]
36. Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2.
Galipeau Y; Siragam V; Laroche G; Marion E; Greig M; McGuinty M; Booth RA; Durocher Y; Cuperlovic-Culf M; Bennett SAL; Crawley AM; Giguère PM; Cooper C; Langlois MA
EBioMedicine; 2021 Dec; 74():103700. PubMed ID: 34861490
[TBL] [Abstract][Full Text] [Related]
37. Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.
Pradenas E; Trinité B; Urrea V; Marfil S; Tarrés-Freixas F; Ortiz R; Rovirosa C; Rodon J; Vergara-Alert J; Segalés J; Guallar V; Valencia A; Izquierdo-Useros N; Noguera-Julian M; Carrillo J; Paredes R; Mateu L; Chamorro A; Toledo R; Massanella M; Clotet B; Blanco J
Cell Rep Med; 2022 Feb; 3(2):100523. PubMed ID: 35233547
[TBL] [Abstract][Full Text] [Related]
38. Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.
Bonhomme ME; Bonhomme CJ; Strelow L; Chaudhari A; Howlett A; Breidenbach C; Hester J; Hammond C; Fuzy M; Harvey L; Swanner V; Ellis J; Greway RR; Pisciella VA; Green T; Kierstead L
PLoS One; 2022; 17(2):e0262922. PubMed ID: 35130298
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.
Rathe JA; Hemann EA; Eggenberger J; Li Z; Knoll ML; Stokes C; Hsiang TY; Netland J; Takehara KK; Pepper M; Gale M
J Infect Dis; 2021 Apr; 223(7):1120-1131. PubMed ID: 33367830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
